Antibiotic Prescription for COPD Exacerbations Admitted to Hospital: European COPD Audit
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Appropriate use of antibiotics in the management of hospitalised patients with COPD exacerbations is defined within the GOLD strategy. This paper analyses the factors associated with antibiotic prescribing in patients to better understand how prescribing may be improved. METHODS: The European COPD audit was a study of clinical care in 384 hospitals from 13 European countries between 2010 and 2011 enrolling 16018 patients. Those admitted to hospital due to a clinician-made diagnosis of exacerbation of COPD at the time of discharge were audited. We defined antibiotic prescribing compliance as consistent with the GOLD 2010 recommendations. Two different multivariate models were used to evaluate factors associated with the prescription of antibiotics and the guideline-compliant prescriptions. RESULTS: Overall 86% of admissions were given antibiotics but only 61.4% cases met the GOLD recommendations. Antibiotics were more likely to be given in hospital and at discharge if received prior to admission. Antibiotic prescription was more likely in patients who met the GOLD recommendations and in those with radiological consolidation but there was also a significant use of antibiotics in patients who did not meet either criterion. Patients cared for on a Respiratory Ward were more likely to receive GOLD compliant antibiotic management. CONCLUSIONS: The present study describes the audited in-hospital antibiotic prescription for COPD exacerbation across different European countries. In general, there is an apparent overuse of antibiotics likely to be associated with both patient and practice-related variables.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In Europe, there are 1,100,000 COPD admissions annually, possibly contributing 14,300–42,900 IA cases [112].”
From Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision (2017) · cites this paper as [112]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
Christ-Crain, M., Jaccard-Stolz, D., Bingisser, R., Gencay, M. M., Huber, P. R., Tamm, M., & Müller, B. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15591-8 · Cited by 1,096 · cited 1×
“Whilst alternative approaches have been proposed and several biomarkers have shown promise in this regard, [3] to date there is no universally accepted test to guide initial clinical decision making at the point of hospital presentation [4, 5].”
BackgroundGuidelines for the management of adult lower respiratory tract infections
Woodhead, M., Blasi, F., Ewig, S., Huchon, G., Leven, M., Ortqvist, A., Schaberg, T., Torres, A., van der Heijden, G., & Verheij, T. J. M. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00055705 · Cited by 895 · cited 3×
“The GOLD strategy update 2010, based on the guidelines for the management of lower respiratory tract infections [7], current at the time of the audit, recommended that for hospital care antibiotics should be given to patients who presented with an increase in all three of the following cardinal symptoms: dyspnea, sput…”
BackgroundMethodInfluentialRelationship of Sputum Color to Nature and Outpatient Management of Acute Exacerbations of COPD
Stockley, R. A., O’Brien, C., Pye, A., & Hill, S. L. (2000) · Chest · doi:10.1378/chest.117.6.1638 · Cited by 535
Guidelines for the management of adult lower respiratory tract infections - Summary
Woodhead, M., Blasi, F., Ewig, S., Garau, J., Huchon, G., Ieven, M., Ortqvist, A., Schaberg, T., Torres, A., van der Heijden, G., et al. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03602.x · Cited by 468
Antibiotics for exacerbations of chronic obstructive pulmonary disease
Vollenweider, D. J., Jarrett, H., Steurer-Stey, C. A., Garcia-Aymerich, J., & Puhan, M. A. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010257 · Cited by 425 · cited 2×
“A seminal Cochrane review showed inconsistent results for outpatients and inpatients not requiring intensive care unit admission [9].”
BackgroundResultInfluence of sex on chronic obstructive pulmonary disease risk and treatment outcomes
Mannino, D., Aryal, S., & Diaz, E. (2014) · International Journal of Chronic Obstructive Pulmonary Disease · doi:10.2147/copd.s54476 · Cited by 173 · cited 1×
“Although reports regarding gender-related differences in COPD expression have provided conflicting results, several studies indicate that COPD has a different clinical presentation and burden of the disease in women as compared to men [19, 20].”
ResultDaniels, J. M. A., Schoorl, M., Snijders, D., Knol, D. L., Lutter, R., Jansen, H. M., & Boersma, W. G. (2010) · CHEST Journal · doi:10.1378/chest.09-2927 · Cited by 144 · cited 1×
“Despite some trials suggesting that the use of antibiotics in exacerbations is associated with a reduced short term mortality [8], other trials have not found an effect [12, 13].”
BackgroundPneumonic and Nonpneumonic Exacerbations of COPD
Huerta, A. H., Crisafulli, E., Menéndez, R., Martínez, R., Soler, N., Guerrero, M., Montull, B., & Torres, A. (2013) · CHEST Journal · doi:10.1378/chest.13-0488 · Cited by 120
Clinical Audit of COPD Patients Requiring Hospital Admissions in Spain: AUDIPOC Study
Pozo-Rodríguez, F., López-Campos, J. L., Álvarez-Martínez, C. J., Castro-Acosta, A. A., Agüero, R., Hueto, J., Hernández, J. H., Barrón, M., Abraira, V., Forte, A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042156 · Cited by 118 · cited 4×
“This variance is similar to that of a cross-sectional European study in primary care carried out in January and February 2008 in six countries (Denmark, Sweden, Lithuania, Russia, Spain and Argentina) which registered all patients with exacerbations during a 3-week period.”
BackgroundInfluentialSelf-citation
Cited by
Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Bongomin, F., Gago, S., Oladele, R., & Denning, D. (2017) · Journal of Fungi · doi:10.3390/jof3040057 · Cited by 2,953
“In Europe, there are 1,100,000 COPD admissions annually, possibly contributing 14,300–42,900 IA cases [112].”
BackgroundMacLeod, M., Papi, A., Contoli, M., Beghé, B., Celli, B. R., Wedzicha, J. A., & Fabbri, L. M. (2021) · Respirology · doi:10.1111/resp.14041 · Cited by 359
Impact and prevention of severe exacerbations of COPD: a review of the evidence
Halpin, D. M., Miravitlles, M., Metzdorf, N., & Celli, B. (2017) · International Journal of Chronic Obstructive Pulmonary Disease · doi:10.2147/copd.s139470 · Cited by 246
“167 In a study conducted in the US, review of medical records indicated that patients with COPD received only 58% of the care recommended by guidelines.”
Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis
Mathioudakis, A. G., Chatzimavridou-Grigoriadou, V., Corlăteanu, A., & Vestbo, J. (2017) · European Respiratory Review · doi:10.1183/16000617.0073-2016 · Cited by 134
Denning, D. W., Perlin, D. S., Muldoon, E. G., Colombo, A. L., Chakrabarti, A., Richardson, M. D., & Sorrell, T. C. (2017) · Emerging Infectious Diseases · doi:10.3201/eid2302.152042 · Cited by 95
CRP-guided antibiotic treatment in acute exacerbations of COPD in hospital admissions
Prins, H. J., Duijkers, R., van der Valk, P., Schoorl, M., Daniels, J. M. A., van der Werf, T. S., & Boersma, W. G. (2019) · European Respiratory Journal · doi:10.1183/13993003.02014-2018 · Cited by 106
Wang, J., Zhang, S.-M., Li, X., Zhang, Y., Xu, Z., & Cao, B. (2016) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2016.04.024 · Cited by 48
Effectiveness of Nationwide COPD Pay-for-Performance Program on COPD Exacerbations in Taiwan
Cheng, S.-L., Li, Y.-R., Huang, N., Yu, C., Wang, H., Lin, M., Chiu, K.-C., Hsu, W., Chen, C., Sheu, C., et al. (2021) · International Journal of COPD · doi:10.2147/copd.s329454 · Cited by 35
Lin, C., & Pang, Q. (2016) · The Clinical Respiratory Journal · doi:10.1111/crj.12519 · Cited by 33
“4% cases met the Global Initiative for Obstructive Lung Disease(GOLD) recommendations.(7) In general, there is an apparent overuse of antibiotic.”
MethodChoi, J., Oh, J. Y., Lee, Y. S., Hur, G. Y., Lee, S. Y., Shim, J. J., Kang, K. H., & Min, K. H. (2019) · International Journal of COPD · doi:10.2147/copd.s197361 · Cited by 35
“Hence, antibiotics are often overused and stray from the GOLD guidelines, as reported by a study conducted in Europe.6 To solve this problem, various biomarkers that distinguish bacterial infections have been studied, which include C-reactive protein (CRP) and procalcitonin.”
MethodClinical and social barriers to antimicrobial stewardship in pulmonary medicine: A qualitative study
Broom, J. K., Broom, A. F., Kirby, E. R., Gibson, A. F., & Post, J. J. (2017) · American Journal of Infection Control · doi:10.1016/j.ajic.2017.03.003 · Cited by 36
Morantes-Caballero, J. A., & Fajardo-Rodríguez, H. A. (2019) · International Journal of COPD · doi:10.2147/copd.s192047 · Cited by 33
“8% and 86%.(19) Likewise, diagnosing pneumonia in patients with exacerbation of COPD of 20.”
BackgroundDevelopment and Relevance of Hypercapnia in COPD
Dave, C., Wharton, S., Mukherjee, R., Faqihi, B. M., Stockley, R. A., & Turner, A. M. (2021) · Canadian Respiratory Journal · doi:10.1155/2021/6623093 · Cited by 23
Management of acute COPD exacerbations in Australia: do we follow the guidelines?
Cousins, J. L., Wood-Baker, R. R., Wark, P. A. B., Yang, I. A., Gibson, P. G., Hutchinson, A. F., Sajkov, D., Hiles, S. A., Samuel, S., & McDonald, V. M. (2020) · ERJ Open Research · doi:10.1183/23120541.00270-2019 · Cited by 21
“A number of studies have identified inappropriate prescription of antibiotic therapy in the AECOPD patient cohort [12, 33, 34].”
Bremmer, D. N., Moffa, M. A., Ma, K., Bean, H., Snatchko, J., Trienski, T. L., Watson, C., & Walsh, T. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy552 · Cited by 17
“Utilizing standard of care with these criteria may lead to antibiotic overutilization as sputum purulence does not always indicate a bacterial infection [5, 6].”
BackgroundPetite, S. E., & Murphy, J. A. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018799696 · Cited by 19
Truppa, C. T., Alonso, B., Clezy, K. R., Déglise, C., Dromer, C., Garelli, S., Jimenez, C., Kanapathipillai, R., Khalife, M., & Repetto, E. C. (2023) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-023-01301-4 · Cited by 23
“…same time, specific focus could be dedicated in better understanding antibiotic prescription practices in some key PHC services where antibiotics are known to be sub-optimally prescribed in HIC—such as in pregnancy [54] or chronic obstructive pulmonary disease (COPD) exacerbations in adults [55].”
BackgroundVanoverschelde, A., Hoey, C. V., Buyle, F. M., Blauwen, N. D., Depuydt, P. O., Braeckel, E. V., & Lahousse, L. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02426-3 · Cited by 16
Bremmer, D. N., DiSilvio, B. E., Hammer, C., Beg, M., Vishwanathan, S., Speredelozzi, D., Moffa, M. A., Hu, K., Abdulmassih, R., Makadia, J. T., et al. (2018) · Journal of General Internal Medicine · doi:10.1007/s11606-018-4312-2 · Cited by 14
“Therefore, the common practice of prescribing antibiotics based on these subjective criteria is likely to lead to unnecessary overuse of antibiotics.(4) As antibiotic resistance is becoming a serious threat to public health,(7) antimicrobial stewardship programs (ASPs) have a significant opportunity to reduce antibiot…”
BackgroundInfluentialTu, Y., Chen, Y., Li, X., Wang, Y., Fang, B., Ren, Y., & Wang, C. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666241308408 · Cited by 19
“7 Therefore, it is important to understand the different changes of immune system in vivo to infectious factors and noninfectious factors.”
Halpin, D. M. G. (2023) · Pragmatic and Observational Research · doi:10.2147/por.s396830 · Cited by 14
Patient's treatment burden related to care coordination in the field of respiratory diseases
Pierucci, P., Santomasi, C., Ambrosino, N., Portacci, A., Diaferia, F., Hansen, K., Odemyr, M., Jones, S., & Carpagnano, G. E. (2021) · Breathe · doi:10.1183/20734735.0006-2021 · Cited by 21
Kodde, C., Bonsignore, M., Köhler, J., Schwegmann, K., & Nachtigall, I. (2024) · Journal of Hospital Infection · doi:10.1016/j.jhin.2024.07.021 · Cited by 14
[Integral approach to the acute exacerbation of chronic obstructive pulmonary disease].
del Castillo, J. M. G., Candel, F. J., de la Fuente, J., Gordo, F., Martín‐Sánchez, F. J., Menéndez, R., Mujal, A., & Barberán, J. (2018) · PubMed · Cited by 11
Ye, Y.-P., Zhao, H., Kang, T., Zhao, L.-H., Li, N., Chen, J., & Peng, X. (2022) · Chronic Respiratory Disease · doi:10.1177/14799731221108516 · Cited by 10
“075 Respiratory rate, breaths/min, median(IQR) 22(5) 21(6) .”
Yang, M., Liu, X., Hu, Q., Li, J., Fu, S., Chen, D., Wu, Y., Luo, A., Zhang, X., Feng, R., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-051939 · Cited by 11
Sheng, W., Huang, L., Gu, X., Wang, Y., Jiang, M., Hu, C., Li, J., Ran, C., Zhang, H., Wang, N., et al. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.12.004 · Cited by 9
Ernst, P., Dahl, M. E., Chateau, D. G., Daneman, N., Quail, J. M., SKETRIS, I. S., Fisher, A., Zhang, J., & Bugden, S. (2019) · International Journal of COPD · doi:10.2147/copd.s226324 · Cited by 9
“This variability in the quality of prescribing for exacerbations across jurisdictions has been seen in other studies but the root causes of these differences require further investigation.(24) Table 1 Frequency Of Antibiotics Used For Initial Treatment Of Acute Exacerbations Of COPD”
ResultA systematic review and Bayesian meta-analysis of the antibiotic treatment courses in AECOPD
Yu, H., Lei, T., Su, X., Zhang, L., Feng, Z., Chen, X., & Liu, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1024807 · Cited by 8
Wang, J., & Cao, B. (2018) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000555 · Cited by 7
Antibiotics for COPD exacerbations: does drug or duration matter? A primary care database analysis
Stolbrink, M., Bonnett, L. J., & Blakey, J. (2019) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2019-000458 · Cited by 8
“However, community-treated exacerbations of COPD are far more common than hospitalisations, and most people admitted have not completed antibiotics in the community, so any effect on the analyses would be modest.(20) There was no explicit coding for repeat or continuous antibiotics in this data set.”
BackgroundBroom, J. K., & Broom, A. F. (2018) · Respirology · doi:10.1111/resp.13334 · Cited by 6
Msolli, M. A., Messous, S., Sekma, A., Ali, K. B. H., Khalil, M. H., Trabelsi, I., Abdelghani, A., Nadia, B. B., Daya, Y. B., Razgallah, R., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251716 · Cited by 6
RetractedInherent immunity and adaptive immunity: Mechanism and role in AECOPD
Wu, L., Zhang, E., Tu, Y., Chen, Y., Wang, C., Ren, Y., & Fang, B. (2025) · Innate Immunity · doi:10.1177/17534259251322612 · Cited by 5
Berry, R., Catteau, L., Caris, M. G., de Boer, M. G. J., Kherabi, Y., Magrini, E., Medioli, F., Murri, R., Ng, B. Y., Peiffer‐Smadja, N., et al. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.01.011 · Cited by 7
Was the implementation strategy of the ProACT trial adequately proactive?
Mathioudakis, A. G., & Vestbo, J. (2019) · Breathe · doi:10.1183/20734735.0338-2018 · Cited by 5
“4% of all hospitalised exacerbations were strictly fulfilling Global Initiative for Chronic Obstructive Lung Disease criteria for antibiotic administration [12].”
BackgroundPetite, S. E., & Murphy, J. A. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa119 · Cited by 7
Huang, L., Wang, J., Gu, X., Sheng, W., Wang, Y., & Cao, B. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-049515 · Cited by 4
Jordan, A. S., Sivapalan, P., Rømer, V., & Jensen, J. S. (2023) · Biomedicines · doi:10.3390/biomedicines11051395 · Cited by 8
Summan, A., Klemperer, K., Kalanxhi, E., McDonnell, A., & Laxminarayan, R. (2025) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2025.107949 · Cited by 3
Díez‐Manglano, J., Iglesias, J. R., Aguilar, J. M. V., Mena, P. A., & Garmendia, G. (2017) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2017.08.004 · Cited by 3
Adwani, S. H., Yuan, C., Alsaleh, L., Pepe, J., & Abusaada, K. (2018) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.12887 · Cited by 2
Mohsin, U. R., Simkhada, N., Pathak, B. D., Dhakal, B., Subedi, B., Thapa, D., Shrestha, B. P., Tandon, O. P., Shrestha, S. K., Sharma, S., et al. (2022) · Journal of Nepal Medical Association · doi:10.31729/jnma.7512 · Cited by 2
Zhou, L., Deng, Y., Liu, K., Liu, H., & Liu, W. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1380939 · Cited by 2
Díez‐Manglano, J., Iglesias, J. R., Aguilar, J. M. V., Mena, P. A., & Garmendia, G. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2017.02.023 · Cited by 1
Antibiotic use in patients with chronic obstructive pulmonary disease: considerations and risks
Sherrell, Z. (2021) · British Journal of Healthcare Management · doi:10.12968/bjhc.2021.0099 · Cited by 1
Biomarkers to guide antibiotic therapy for COPD exacerbations
Mathioudakis, A. G., Janjua, S., Normansell, R., & Vestbo, J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013148
Antivirals for Virus Induced Exacerbations of Asthma and COPD Treatment
Grigorescu, C., Antonela, A. S., Oțelea, M. R., Antohe, I., Fildan, A. P., Anton, A. I., & Tofolean, D. E. (2018) · Ars medica tomitana · doi:10.2478/arsm-2018-0027
“In COPD patients, viral respiratory infections or combined viral-bacterial infection can have a significant impact on diseaserelated morbidity by determining more severe exacerbations (9-11).”
BackgroundCOPD as an exemplar of a chronic health condition
Roberts, C. M., López-Campos, J. L., & Breyer‐Kohansal, R. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108855440.006
Self-citationvan Schaik, M., Veen, H. I. ’., Brusselle, G., Boersma, W. G., Bresser, P., Reijers, M. H. E., van Dooren, Y. P. A., Djamin, R. S., Melle, M. L. D. V., van den Berg, J. W., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-963649/v1
Thành, N. M., Phương, T. T., Nhi, N. T. Ý., & Quỳnh, B. T. H. (2022) · Tạp chí Y học Việt Nam · doi:10.51298/vmj.v510i2.1963
Shah, M., Trivedi, N. A., & Chauhan, J. (2023) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20230398 · Cited by 1
Antibiotic Drugs and Noninvasive Ventilation: Indications, Classification and Clinical Results
Silva, C. M. (2023) · Noninvasive ventilation. The essentials · doi:10.1007/978-3-031-44626-9_16
Messous, S., Rekik, A., Keraani, L., Hamed, R., Toumia, M., Dhaoui, R., Sekma, A., Ali, K. B. H., Sassi, S. B., Kouraichi, C., et al. (2025) · Clinical Therapeutics · doi:10.1016/j.clinthera.2025.04.020
Berry, R., Catteau, L., Caris, M. G., de Boer, M. G. J., Kherabi, Y., Magrini, E., Medioli, F., Murri, R., Ng, B. Y., Peiffer‐Smadja, N., et al. (2025) · medRxiv · doi:10.1101/2025.10.08.25337205
Gomaa, S. A. I., Radwan, W. A., Nassar, Y. S., Elhenawy, Y. H., & Elansary, M. G. (2025) · The Egyptian Journal of Radiology and Nuclear Medicine · doi:10.1186/s43055-025-01566-2
“Ultrasound methods for estimating diaphragmatic thickness and diaphragmatic excursion in the zone of apposition have been published by numerous authors [7] .”
Vanoverschelde, A., Hoey, C. V., Buyle, F. M., Blauwen, N. D., Depuydt, P., Braeckel, E. V., & Lahousse, L. (2023) · Figshare · doi:10.6084/m9.figshare.22697201
Quality of antibiotics prescription in hospitals in Burkina Faso: a multispecialty clinical audit
Diallo, D., Sore, S., Yao, S., Kambou, S. P., Hema, Y., Zongo, S., Rouamba, M., Manigart, O., Poda, D. A., Ouedraogo, A. S., et al. (2026) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-026-01743-6
van Krimpen, S. J., Koenen, H. J. P. M., van Cranenbroek, B., van Rijssen, E., van Smoorenburg, L. H., Staats-Niemeijer, A., Wit, N. C. J. D., Verweij, J. J., Franssen, F. M. E., Gosker, H. R., et al. (2026) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1080/15412555.2026.2733469
Metadata
- Authors
- López-Campos, J. L., Hartl, S., Pozo-Rodriguez, F., Roberts, C. M., & on behalf of the European COPD Audit team
- Affiliations
- Ludwig Boltzmann Institute for Lung Health (AT)
- University of London (GB)
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-04-23
- Volume
- 10
- Issue
- 4
- Pages
- e0124374
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4408103
- OpenAlex
- W2028953801
- Cited by
- 59
- References
- 27
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 3 · 2023: 8 · 2022: 5 · 2021: 7 · 2020: 3 · 2019: 6 · 2018: 9 · 2017: 6 · 2016: 3
- FWCI
- 4.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- AstraZeneca
- GlaxoSmithKline
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Epidemiology › Pneumonia and Respiratory Infections
- Keywords
- COPD exacerbations, antibiotic prescribing, guideline adherence, antibiotic overuse, hospitalized patients
- MeSH terms
- Anti-Bacterial Agents, Europe, Humans, Medical Audit, Patient Admission, Drug Utilization Review, Pulmonary Disease, Chronic Obstructive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.